European League Against Rheumatism (EULAR) Congress 2019

EULAR calls for privacy, transparency when using big data in RMD research

Elvira Manzano, 20190801130000

Privacy and transparency are among the core points to consider when utilizing big data in rheumatic and musculoskeletal disorders (RMDs), according to the first EULAR-endorsed recommendations for use of big datasets in research.

Tocilizumab-methotrexate combo shows promise as first-line treatment for early RA

Roshini Claire Anthony, 20190717140303

A combination of tocilizumab and methotrexate reduced disease activity at 2 years compared with methotrexate plus prednisone in patients with early rheumatoid arthritis (RA), an effect not demonstrated with tocilizumab monotherapy.

Low-dose prednisolone helps relieve pain in hand osteoarthritis

Pearl Toh, 20190706150000

Patients with painful hand osteoarthritis can finally get relief from pain with low-dose prednisolone, suggests a study presented at EULAR 2019.

Occupational inorganic dust exposure tied to gout risk

Elaine Soliven, 20190705000000

Occupational exposure to inorganic dust, particularly asbestos, silica, and coal, was associated with an increased risk of developing gout, according to a study presented at EULAR 2019.

Being overweight may affect psoriatic arthritis disease severity

Roshini Claire Anthony, 20190703140702

Being overweight may have an impact on disease severity in psoriatic arthritis, according to a study presented at EULAR 2019.

Upadacitinib continues to improve RA symptoms in extension studies

Audrey Abella, 20190703100000

The selective Janus kinase 1 inhibitor upadacitinib demonstrated sustained efficacy and safety beyond 12 weeks in patients with moderate-to-severe rheumatoid arthritis (RA) who had inadequate response or were refractory to disease-modifying antirheumatic drugs (DMARDs), according to the interim results of the ongoing extension phases of SELECT-NEXT* and SELECT-BEYOND** presented at EULAR 2019.

IBD, T1D may be risk factors for RA

Elaine Soliven, 20190703000000

Both inflammatory bowel disease (IBD) and type 1 diabetes (T1D) are highly prevalent among patients who eventually develop rheumatoid arthritis (RA), indicating that these two conditions are potential risk factors for RA, according to a study presented at EULAR 2019.

Baricitinib improves clinical, functional, radiographic outcomes in RA

Audrey Abella, 20190702100000

Early use of the oral Janus kinase 1/2 inhibitor baricitinib led to enhanced clinical, functional, and radiographic efficacy compared with methotrexate monotherapy in patients with rheumatoid arthritis (RA), according to data presented at EULAR 2019.

Tildrakizumab shows promise in psoriatic arthritis

Audrey Abella, 20190701100000

The anti-interleukin (IL)-23p19 monoclonal antibody tildrakizumab showed better efficacy over placebo, along with a favourable safety profile, in patients with active psoriatic arthritis (PsA), according to a phase IIb study presented at EULAR 2019.

Glucocorticoid tapering encouraged for patients with stable RA

Pearl Toh, 20190628190000

Glucocorticoid therapy can be safely tapered while maintaining high treatment success rates in patients with rheumatoid arthritis (RA) who had achieved disease control on tocilizumab, at the cost of a slight loss of disease control, suggests a randomized study presented at the EULAR 2019 Congress.